Open-label, Randomized, Active-controlled Study of LEV Used as Monotherapy in Patients With Partial-Onset Seizures
Open-label, Randomized, Active-controlled Study of LEV Used as Monotherapy in Patients With Partial-Onset Seizures
To demonstrate the non-inferiority of Levetiracetam (1000 mg/day) versus Carbamazepine
 Immediate-Release (400 mg/day) used as monotherapy for at least 6 months in a Chinese
 population with newly or recently diagnosed Epilepsy who are experiencing Partial-Onset
 Seizures (POS).
Inclusion Criteria:

 -  Subject is of Chinese origin and ≥ 16 years of age

 -  Subject is newly or recently diagnosed with Epilepsy, having experienced unprovoked
 Partial-Onset Seizures (POS)

 -  Subject has experienced at least 2 unprovoked seizures in the year preceding
 randomization, of which at least 1 unprovoked seizure occurred in the 3 months
 preceding randomization

 -  Subject has had an Electroencephalogram (EEG) and a brain Computed Tomography (CT)
 scan or brain Magnetic Resonance Imaging (MRI) scan consistent with a diagnosis of
 Epilepsy with POS

 Exclusion Criteria:

 -  Subject tests positive for human leukocyte antigen major histocompatibility complex,
 class I,B (HLA-B)* 1502 allele

 -  Subject has a history or presence of seizures of other types than Partial-Onset
 Seizures (POS)

 -  Subject has only experienced type IA nonmotor seizures

 -  Subject has a history or presence of seizures occurring only in clustered patterns

 -  Subject has a history of clinical or Electroencephalogram (EEG) findings suggestive of
 Idiopathic Generalized Epilepsy prior to randomization

 -  Subject has current or previous diagnosis of pseudoseizures, conversion disorders, or
 other nonepileptic ictal events that could be confused with seizures

 -  Subject has a history of Status Epilepticus